Different results from long-term follow-up of the PARTNER-3 and Evolut trials evaluating TAVR vs surgery in low-surgical-risk patients are leading to some interesting discussions.
The Trilogy transcatheter aortic valve replacement system was safe and effective for high-risk surgical patients with aortic regurgitation, improving LV remodeling and function, in the ALIGN-AR trial.
Left atrial appendage occlusion in the same procedure with transcatheter aortic valve replacement proved non-inferior to TAVR plus medical therapy in AF and aortic stenosis, in the WATCH-TAVR study.
While the new drug reduced hematoma expansion compared with usual care, it was also associated with an increase in thrombotic events in the ANNEXa-I study.